Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (TOPIC)

20 de janeiro de 2017 atualizado por: Sanofi

An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period

The primary objective was to demonstrate the effect of teriflunomide (HMR1726) (14 milligram per day [mg/day] and 7 mg/day), in comparison to placebo, for reducing conversion of participants presenting with their first clinical episode consistent with multiple sclerosis (MS) to clinically definite multiple sclerosis (CDMS).

The secondary objectives were:

  • To demonstrate the effect of teriflunomide, in comparison to placebo, on:

    • Reducing conversion to definite multiple sclerosis (DMS)
    • Reducing annualized relapse rate (ARR)
    • Reducing disease activity/progression as measured by Magnetic Resonance Imaging (MRI)
    • Reducing accumulation of disability for at least 12 weeks as measured by the Expanded Disability Status Scale (EDSS)
    • Proportion of disability-free participants as assessed by the EDSS
    • Reducing participant-reported fatigue
  • To evaluate the safety and tolerability of teriflunomide
  • To evaluate the pharmacokinetics (PK) of teriflunomide
  • Optional pharmacogenomic testing aimed at assessing the association between the main enzyme systems of teriflunomide metabolism and hepatic safety, and other potential associations between gene variations and clinical outcomes

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

The study consisted of 4 periods:

  • Screening period: up to 4 weeks,
  • Placebo-controlled treatment period: up to 108 weeks (at least 24 weeks for participants who experienced conversion to CDMS),
  • Extension treatment period (without placebo-control): the extension period continued until teriflunomide was commercially available in participant's country of residence.
  • Post-treatment washout period: 4 weeks after last treatment intake.

The maximal duration of the study period per participant was expected to be 116 weeks if he/she did not continue in the extension treatment period.

Tipo de estudo

Intervencional

Inscrição (Real)

618

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Alemanha
      • Bayreuth, Alemanha, 95445
        • Investigational Site Number 6801
      • Berlin, Alemanha, 10713
        • Investigational Site Number 6810
      • Berlin, Alemanha, 10785
        • Investigational Site Number 6805
      • Erbach, Alemanha, 64711
        • Investigational Site Number 6807
      • Essen, Alemanha, 45122
        • Investigational Site Number 6803
      • Hannover, Alemanha, 30625
        • Investigational Site Number 6809
      • Ludwigshafen, Alemanha, 67063
        • Investigational Site Number 6804
      • Minden, Alemanha, 32429
        • Investigational Site Number 6815
      • Münster, Alemanha, 48149
        • Investigational Site Number 6802
      • Wiesbaden, Alemanha, 65191
        • Investigational Site Number 6806
  • Austrália
      • Geelong, Austrália, 3220
        • Investigational Site Number 1405
      • Heidelberg, Austrália, 3081
        • Investigational Site Number 1404
      • Hobart, Austrália, 7001
        • Investigational Site Number 1407
      • Parkville, Austrália, 3050
        • Investigational Site Number 1401
  • Bulgária
      • Pleven, Bulgária, 5800
        • Investigational Site Number 5312
      • Sofia, Bulgária, 1000
        • Investigational Site Number 5307
      • Sofia, Bulgária, 1407
        • Investigational Site Number 5304
      • Sofia, Bulgária, 1431
        • Investigational Site Number 5309
      • Sofia, Bulgária, 1527
        • Investigational Site Number 5303
      • Sofia, Bulgária, 1606
        • Investigational Site Number 5306
  • Canadá
      • Greenfield Park, Canadá, J4V 2J2
        • Investigational Site Number 5402
      • London, Canadá, N6A 5A5
        • Investigational Site Number 5403
      • Montreal, Canadá, H1T 2M4
        • Investigational Site Number 5409
      • Ottawa, Canadá, K1H 8L6
        • Investigational Site Number 5401
      • Quebec, Canadá, G1J 1Z4
        • Investigational Site Number 5406
      • Sherbrooke, Canadá, J1H 5N4
        • Investigational Site Number 5408
      • Toronto, Canadá, M4N 3M5
        • Investigational Site Number 5410
      • Toronto, Canadá, M5B 1W8
        • Investigational Site Number 5404
  • Chile
      • Santiago, Chile, 760-0746
        • Investigational Site Number 5602
      • Santiago, Chile
        • Investigational Site Number 5601
      • Santiago, Chile
        • Investigational Site Number 5606
      • Viña Del Mar, Chile, 2520997
        • Investigational Site Number 5605
  • Dinamarca
      • Aarhus C, Dinamarca, 8000
        • Investigational Site Number 6002
      • Esbjerg, Dinamarca, 6700
        • Investigational Site Number 6004
  • Estados Unidos
    • Alabama
      • Cullman, Alabama, Estados Unidos, 35058
        • Investigational Site Number 8965
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85013-4496
        • Investigational Site Number 8954
      • Phoenix, Arizona, Estados Unidos, 85060
        • Investigational Site Number 8946
    • Colorado
      • Fort Collins, Colorado, Estados Unidos, 80528
        • Investigational Site Number 8962
    • Florida
      • Maitland, Florida, Estados Unidos, 32761
        • Investigational Site Number 8920
      • St. Petersburg, Florida, Estados Unidos, 33701
        • Investigational Site Number 8953
    • Indiana
      • Ft. Wayne, Indiana, Estados Unidos, 63104
        • Investigational Site Number 8914
      • Indianapolis, Indiana, Estados Unidos, 46256
        • Investigational Site Number 8940
    • Louisiana
      • Shreveport, Louisiana, Estados Unidos, 71103
        • Investigational Site Number 8922
    • Michigan
      • Grand Rapids, Michigan, Estados Unidos, 49503
        • Investigational Site Number 8955
      • Traverse City, Michigan, Estados Unidos, 49684
        • Investigational Site Number 8949
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63104
        • Investigational Site Number 8937
    • New Mexico
      • Albuquerque, New Mexico, Estados Unidos, 87131
        • Investigational Site Number 8951
    • New York
      • New York, New York, Estados Unidos, 10029-6574
        • Investigational Site Number 8925
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28204
        • Investigational Site Number 8941
    • Ohio
      • Dayton, Ohio, Estados Unidos, 45409
        • Investigational Site Number 8924
    • Tennessee
      • Round Rock, Tennessee, Estados Unidos, 78681
        • Investigational Site Number 8905
    • Vermont
      • Burlington, Vermont, Estados Unidos, 05401
        • Investigational Site Number 8930
    • Washington
      • Seattle, Washington, Estados Unidos, 98122
        • Investigational Site Number 8963
  • Estônia
      • Tallinn, Estônia, 10617
        • Investigational Site Number 6201
      • Tartu, Estônia, 50406
        • Investigational Site Number 6203
  • Federação Russa
      • Kazan, Federação Russa, 420021
        • Investigational Site Number 7907
      • Nizhny Novgorod, Federação Russa, 603000
        • Investigational Site Number 7909
      • Nizhny Novgorod, Federação Russa, 603076
        • Investigational Site Number 7906
      • Nizhny Novgorod, Federação Russa, 603126
        • Investigational Site Number 7904
      • Novosibirsk, Federação Russa, 630007
        • Investigational Site Number 7912
      • Rostov-On-Don, Federação Russa, 344085
        • Investigational Site Number 7910
      • Smolensk, Federação Russa, 214019
        • Investigational Site Number 7905
      • St-Petersburg, Federação Russa, 194044
        • Investigational Site Number 7911
  • Finlândia
      • Helsinki, Finlândia, 00100
        • Investigational Site Number 6405
      • Kuopio, Finlândia, 70210
        • Investigational Site Number 6403
      • Turku, Finlândia, 20100
        • Investigational Site Number 6401
  • França
      • Besancon, França, 25030
        • Investigational Site Number 6611
      • Clermont Ferrand Cedex 1, França, 63003
        • Investigational Site Number 6601
      • Lille Cedex, França, 59037
        • Investigational Site Number 6609
      • Montpellier Cedex 05, França, 34295
        • Investigational Site Number 6604
      • Nancy Cedex, França, 54036
        • Investigational Site Number 6612
      • Nantes Cedex 01, França, 44093
        • Investigational Site Number 6605
      • Nice Cedex, França, 06002
        • Investigational Site Number 6602
      • Nimes, França, 30029
        • Investigational Site Number 6614
      • Strasbourg Cedex, França, 67091
        • Investigational Site Number 6607
  • Hungria
      • Budapest, Hungria, 1076
        • Investigational Site Number 7101
      • Budapest, Hungria, 1145
        • Investigational Site Number 7103
      • Esztergom, Hungria, 2500
        • Investigational Site Number 7108
      • Veszprém, Hungria, 8200
        • Investigational Site Number 7105
  • Lituânia
      • Klaipeda, Lituânia, LT-92288
        • Investigational Site Number 7402
      • Siauliai, Lituânia, LT-76231
        • Investigational Site Number 7403
      • Vilnius, Lituânia, LT-08661
        • Investigational Site Number 7401
  • México
      • Chihuahua, México, 31203
        • Investigational Site Number 7501
      • Guadalajara, México, 45110
        • Investigational Site Number 7502
  • Peru
      • Edirne, Peru
        • Investigational Site Number 8304
      • Istanbul, Peru, 34390
        • Investigational Site Number 8309
      • Istanbul, Peru, 34400
        • Investigational Site Number 8315
      • Istanbul, Peru
        • Investigational Site Number 8308
      • Istanbul, Peru
        • Investigational Site Number 8310
      • Istanbul, Peru
        • Investigational Site Number 8312
      • Izmir, Peru, 35100
        • Investigational Site Number 8305
      • Izmir, Peru, 35340
        • Investigational Site Number 8301
      • Izmir, Peru, 35380
        • Investigational Site Number 8303
      • Izmit, Peru, 41380
        • Investigational Site Number 8302
      • Trabzon, Peru, 61080
        • Investigational Site Number 8314
  • Polônia
      • Gdansk, Polônia, 80-803
        • Investigational Site Number 7709
      • Lodz, Polônia, 93-513
        • Investigational Site Number 7710
      • Warszawa, Polônia, 02-097
        • Investigational Site Number 7701
      • Warszawa, Polônia, 02-957
        • Investigational Site Number 7703
      • Warszawa 44, Polônia, 04-141
        • Investigational Site Number 7707
  • Reino Unido
      • Liverpool, Reino Unido, L9 7LJ
        • Investigational Site Number 8709
      • London, Reino Unido, E1 1BB
        • Investigational Site Number 8701
      • London, Reino Unido, SW17 0QT
        • Investigational Site Number 8704
      • Newcastle Upon Tyne, Reino Unido, NE1 4LP
        • Investigational Site Number 8706
      • Nottingham, Reino Unido, NG7 2UH
        • Investigational Site Number 8705
      • Plymouth, Reino Unido, PL6 5BX
        • Investigational Site Number 8708
      • Salford, Reino Unido, M6 8HD
        • Investigational Site Number 8707
      • Sheffield, Reino Unido, S10 2JF
        • Investigational Site Number 8702
  • República Checa
      • Brno, República Checa, 65691
        • Investigational Site Number 5801
      • Hradec Kralove, República Checa, 50005
        • Investigational Site Number 5803
      • Olomouc, República Checa, 77520
        • Investigational Site Number 5804
      • Ostrava - Poruba, República Checa, 70852
        • Investigational Site Number 5805
  • Romênia
      • Bucuresti, Romênia, 020125
        • Investigational Site Number 7803
      • Bucuresti, Romênia, 050098
        • Investigational Site Number 7806
      • Cluj-Napoca, Romênia, 400012
        • Investigational Site Number 7805
      • Cluj-Napoca, Romênia, 400012
        • Investigational Site Number 7807
      • Timisoara, Romênia, 300736
        • Investigational Site Number 7808
  • Ucrânia
      • Chernihiv, Ucrânia, 14029
        • Investigational Site Number 8507
      • Dnipropetrovsk, Ucrânia, 49027
        • Investigational Site Number 8501
      • Donets'K, Ucrânia, 83099
        • Investigational Site Number 8511
      • Kharkiv, Ucrânia, 61018
        • Investigational Site Number 8506
      • Kharkiv, Ucrânia, 61178
        • Investigational Site Number 8504
      • Kiev, Ucrânia, 03110
        • Investigational Site Number 8508
      • Lutsk, Ucrânia, 43005
        • Investigational Site Number 8512
      • Lviv, Ucrânia, 79010
        • Investigational Site Number 8505
      • Poltava, Ucrânia, 36011
        • Investigational Site Number 8510
      • Vinnytsya, Ucrânia, 21005
        • Investigational Site Number 8503
      • Zaporizhzhya, Ucrânia, 69000
        • Investigational Site Number 8502
  • Áustria
      • Innsbruck, Áustria, 6020
        • Investigational Site Number 4004
      • Linz, Áustria, 4020
        • Investigational Site Number 4005
      • Wien, Áustria, 1010
        • Investigational Site Number 4001

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 55 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • First acute or subacute, well-defined neurological event consistent with demyelination (that is, optic neuritis confirmed by an ophthalmologist, spinal cord syndrome, brainstem/cerebellar syndromes)
  • Onset of MS symptoms occurring within 90 days of randomization
  • A screening MRI scan with 2 or more T2 lesions at least 3 millimeter (mm) in diameter that are characteristic of MS

Exclusion Criteria:

  • Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major systemic disease
  • Significantly impaired bone marrow function
  • Pregnancy or nursing
  • Alcohol or drug abuse
  • Use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment
  • Any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador de Placebo: Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg

Core treatment period: Placebo matched to teriflunomide tablet once daily orally.

Extension treatment period: Re-randomized in 1:1 ratio to either teriflunomide 7 mg or 14 mg once daily orally.
Medicamento: Teriflunomide
Film-coated tablet Oral administration
Outros nomes:
  • Aubagio
  • HMR1726
Medicamento: Placebo
Film-coated tablet Oral administration
Experimental: Teriflunomide 7 mg/7 mg

Core treatment period: Teriflunomide 7 mg tablet once daily orally.

Extension treatment period: Teriflunomide 7 mg tablet once daily orally.
Medicamento: Teriflunomide
Film-coated tablet Oral administration
Outros nomes:
  • Aubagio
  • HMR1726
Experimental: Teriflunomide 14 mg/14 mg

Core treatment period: Teriflunomide 14 mg tablet once daily orally.

Extension treatment period: Teriflunomide 14 mg tablet once daily orally.
Medicamento: Teriflunomide
Film-coated tablet Oral administration
Outros nomes:
  • Aubagio
  • HMR1726

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Core Treatment Period: Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS)
Prazo: Up to a maximum of 108 weeks depending on time of enrollment
Conversion to CDMS was defined by the occurrence of a relapse, which was defined as a new neurological abnormality separated by at least 30 days from onset of a preceding clinical event, presented for at least 24 hours and occurred in the absence of fever or known infection. Percent probability of conversion at 24, 48, and 108 weeks was estimated using Kaplan-Meier method.
Up to a maximum of 108 weeks depending on time of enrollment

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Core Treatment Period: Time to Conversion to Definite Multiple Sclerosis (DMS)
Prazo: Up to a maximum of 108 weeks depending on time of enrollment
Conversion to DMS was demonstrated by dissemination of MRI lesions in time (as per McDonald criteria) or a relapse, whichever occurs first. MRI Imaging criteria were detection of Gadolinium (Gd) enhancement at least 3 months after onset of initial clinical event, if not at site corresponding to initial event; detection of new T2 lesion if it appears at any time compared with reference scan (done at time of screening) done at least 30 days after onset of the initial clinical event. Occurrence of relapse was defined as new neurological abnormality separated by at least 30 days from onset of preceding clinical event, present for at least 24 hours and occurring in absence of fever or known infection. New clinical abnormality (neurological sign) that is consistent with participant's symptoms with increase in at least one Functional System (FS) or EDSS score compared to last EDSS assessment. Percent probability of conversion at 24, 48, and 108 weeks was estimated using Kaplan-Meier method.
Up to a maximum of 108 weeks depending on time of enrollment
Core Treatment Period: Annualized Relapse Rate (ARR)
Prazo: Up to a maximum of 108 weeks depending on time of enrollment
ARR is the total number of confirmed relapses that occurred during the treatment period divided by the total number of patient-years treated. Each episode of relapse (appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever) was to be confirmed by an increase in EDSS score or Functional System scores. ARR was assessed using Poisson regression model with robust error variance. To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses onset between randomization date and last dose date as the response variable, treatment, region and baseline monofocal/multifocal status as covariates, and log-transformed treatment duration as an offset variable).
Up to a maximum of 108 weeks depending on time of enrollment
Core Treatment Period: Brain Magnetic Resonance Imaging (MRI) Assessment: Change From Baseline in Total Lesion Volume at Week 108
Prazo: Baseline, Week 108
The total lesion volume (burden of disease) is the total volumes of hyperintense on T2 plus hypointense on T1 as measured by MRI scan. Least-square means were estimated using a Mixed-effect model with repeated measures (MMRM) on cubic root transformed volume data with factors for treatment, baseline monofocal/multifocal status, region, visit, treatment-by-visit interaction, cubic root transformed baseline burden of disease, and baseline-by-visit interaction.
Baseline, Week 108
Core Treatment Period: Brain MRI Assessment: Number of Gadolinium Enhancing (Gd-enhancing) T1-lesions Per MRI Scan (Poisson Regression Estimates)
Prazo: Up to a maximum of 108 weeks depending on time of enrollment
Number of Gd-enhancing T1-lesions per scan is the total number of Gd-enhancing T1-lesions that occurred during the treatment period divided by the total number of scans performed during the treatment period. To account for the different numbers of scans performed among the participants, a Poisson regression model with robust error variance was used (total number of Gd-enhancing T1-lesions as response variable, treatment, baseline monofocal/multifocal status, region and baseline number of Gd-enhancing T1-lesions as covariates, and log-transformed number of scans as an offset variable).
Up to a maximum of 108 weeks depending on time of enrollment
Core Treatment Period: Brain MRI Assessment: Volume of Gadolinium Enhancing (Gd-enhancing) T1-lesions Per MRI Scan
Prazo: Up to a maximum of 108 weeks depending on time of enrollment
Total volume of Gd-enhancing T1-lesions per scan is the sum of the volumes of Gd-enhancing T1-lesions observed during the treatment period divided by the total number of scans performed during the treatment period. To account for the different numbers of scans performed among the participants, a Poisson regression model with robust error variance was used (total number of Gd-enhancing T1-lesions as response variable, treatment, baseline monofocal/multifocal status, region and baseline number of Gd-enhancing T1-lesions as covariates, and log-transformed number of scans as an offset variable).
Up to a maximum of 108 weeks depending on time of enrollment
Core Treatment Period: Brain MRI Assessment: Change From Baseline in Volume of Hypointense Post-Gadolinium T1 Lesion Component
Prazo: Baseline, Week 108
Volume of hypointense post-gadolinium T1 lesion component was measured by MRI scan. Least-square means were estimated using a Mixed-effect model with repeated measures (MMRM) on cubic root transformed volume data adjusted for baseline monofocal/multifocal status, region, visit, treatment-by-visit interaction, cubic root transformed baseline value, and baseline-by-visit interaction
Baseline, Week 108
Core Treatment Period: Brain MRI Assessment: Change From Baseline in Volume of T2 Lesion Component
Prazo: Baseline, Week 108
Volume of T2 lesion component was measured by MRI scan. Least-square means were estimated using a Mixed-effect model with repeated measures (MMRM) on cubic root transformed volume data adjusted for baseline monofocal/multifocal status, region, visit, treatment-by-visit interaction, cubic root transformed baseline value, and baseline-by-visit interaction.
Baseline, Week 108
Core Treatment Period: Brain MRI Assessment: Percent Change From Baseline in Atrophy
Prazo: Baseline, Week 108
Atrophy was measured by MRI scan.
Baseline, Week 108
Core Treatment Period: Time to 12-Week Sustained Disability Progression
Prazo: Up to a maximum of 108 weeks depending on time of enrollment
The 12-week sustained disability progression was defined as increase from baseline of at least 1-point in EDSS score (at least 0.5-point for participants with baseline EDSS score of greater than [>] 5.5) that persisted for at least 12 weeks. Percent probability of participants free of 12-week sustained disability progression at 24, 48, and 108 weeks was estimated using Kaplan-Meier method.
Up to a maximum of 108 weeks depending on time of enrollment
Core Treatment Period: Change From Baseline in EDSS at Week 108
Prazo: Baseline, Week 108
EDSS is an ordinal scale in half-point increments that qualifies disability in participants with MS. It consists of 8 ordinal rating scales assessing seven functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS). Least-square means were estimated using a Mixed-effect model with repeated measures (MMRM) on cubic root transformed volume data adjusted for baseline monofocal/multifocal status, region, visit, treatment-by-visit interaction, baseline value and baseline-by-visit interaction
Baseline, Week 108
Core Treatment Period: Change From Baseline in Fatigue Impact Scale (FIS) Total Score at Week 108
Prazo: Baseline, Week 108
FIS is a participant-reported scale that qualifies the impact of fatigue on daily life in participants with MS. It consists of 40 statements that measure fatigue in three areas; physical, cognitive, and social. FIS total score ranges from 0 (no problem) to 160 (extreme problem). Least-square means were estimated using a Mixed-effect model with repeated measures [MMRM] on FIS total score data adjusted for or baseline monofocal/multifocal status, region, visit, treatment-by-visit interaction, baseline value and baseline-by-visit interaction.
Baseline, Week 108
Core Treatment Period: Overview of Adverse Events (AEs)
Prazo: From first study drug intake up to 112 days after last intake in the placebo-controlled period or up to first intake in the extension treatment period, whichever occurred first
AEs are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.
From first study drug intake up to 112 days after last intake in the placebo-controlled period or up to first intake in the extension treatment period, whichever occurred first
Extension Treatment Period: Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS)
Prazo: From randomization in the core period up to 390 Weeks (Extension treatment period [maximum exposure: 283 Weeks])
Conversion to CDMS was defined by the occurrence of a relapse, which was defined as a new neurological abnormality separated by at least 30 days from onset of a preceding clinical event, presented for at least 24 hours and occurred in the absence of fever or known infection. Percent probability of conversion was estimated using Kaplan-Meier method.
From randomization in the core period up to 390 Weeks (Extension treatment period [maximum exposure: 283 Weeks])
Extension Treatment Period: Overview of Adverse Events (AEs)
Prazo: From re-randomization up to 283 Weeks
AEs are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study. Safety population included all randomized population who actually received at least 1 dose of the IMP in extension and analyzed according to the treatment actually received in core study followed by treatment actually received in the extension treatment period.
From re-randomization up to 283 Weeks

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Core Treatment Period: Liver Function: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA)
Prazo: From first study drug intake up to 112 days after last intake in the placebo-controlled period or up to first intake in the extension treatment period, whichever occurred first

PCSA values are abnormal values considered medically important by the Sponsor according to predefined criteria based on literature review.

Hepatic parameters thresholds were defined as follows:

  • Alanine Aminotransferase (ALT) >3, 5, 10 or 20 upper limit of normal(ULN);
  • Aspartate aminotransferase (AST) >3, 5, 10 or 20 ULN;
  • Alkaline Phosphatase >1.5 ULN;
  • Total Bilirubin (TB) >1.5, 2, or 3 ULN;
  • ALT >3 ULN and TB >2 ULN.
From first study drug intake up to 112 days after last intake in the placebo-controlled period or up to first intake in the extension treatment period, whichever occurred first

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Sanofi

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de fevereiro de 2008

Conclusão Primária (Real)

1 de dezembro de 2012

Conclusão do estudo (Real)

1 de fevereiro de 2016

Datas de inscrição no estudo

Enviado pela primeira vez

14 de fevereiro de 2008

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de fevereiro de 2008

Primeira postagem (Estimativa)

25 de fevereiro de 2008

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de março de 2017

Última atualização enviada que atendeu aos critérios de controle de qualidade

20 de janeiro de 2017

Última verificação

1 de janeiro de 2017

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • EFC6260
  • HMR1726D-3005 (Outro identificador: HMR)
  • 2006-001152-12 (Número EudraCT)

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever